As lawmakers looked to reduce sky-high consumer prices, a bill was proposed that would target cartels in the hopes of reducing costs across markets. But Switzerland’s Parliament has reportedly rejected the legislation, after years of debate.
According to reports, the bill had been in the works for about six years. Opponents said the bill would have allowed too-broad government intervention in the economy and ultimately burden companies and consumers.
But after Parliament rejected the bill Wednesday, proponents of the legislation said the ultimately losers are small- and medium-sized businesses.
A top champion of the law, Prisca Bierrer-Heimo of the Social Democrats and president of the Consumer Protection Foundation, argued consumers will not likely see government attempts to lower consumer costs anytime soon.
The legislation would have tackled barriers to entry for parallel imports. Reports say Swiss manufacturers have been found to ban distributors from reselling Swiss products to Swiss retailers at lower prices.
Full content: Swiss Info
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan